CL2017002240A1 - Formas cristalinas del compuesto 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol metanosulfonato; composición farmacéutica; usos en el tratamiento de neoplasias hematológicas avanzadas (divisional solicitud 263-2016). - Google Patents

Formas cristalinas del compuesto 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol metanosulfonato; composición farmacéutica; usos en el tratamiento de neoplasias hematológicas avanzadas (divisional solicitud 263-2016).

Info

Publication number
CL2017002240A1
CL2017002240A1 CL2017002240A CL2017002240A CL2017002240A1 CL 2017002240 A1 CL2017002240 A1 CL 2017002240A1 CL 2017002240 A CL2017002240 A CL 2017002240A CL 2017002240 A CL2017002240 A CL 2017002240A CL 2017002240 A1 CL2017002240 A1 CL 2017002240A1
Authority
CL
Chile
Prior art keywords
amino
pyridin
trifluoromethyl
triazin
propan
Prior art date
Application number
CL2017002240A
Other languages
English (en)
Inventor
Samuel V Agresta
Chong-Hui Gu
David Schenkein
Hua Yang
Liting Guo
Zhen Tang
Jianming Wang
Yanfeng Zhang
Yan Zhou
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/081170 external-priority patent/WO2015018060A1/en
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CL2017002240A1 publication Critical patent/CL2017002240A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>SE DESCRIBE UNA FORMA CRISTALINA AISLADA DE 2-METIL-1-[(4-[6-(TRIFLUOROMETIL)PIRIDIN-2-IL]-6-{[2-(TRIFLUOROMETIL)PIRIDIN-4-IL]AMINO}-1,3,5- TRIAZIN-2-IL)AMINO]PROPAN-2-OL METANOSULFONATO, DONDE DICHA FORMA CRISTALINA AISLADA ES: I) LA FORMA 3, TIENE UN PATRÓN DE DIFRACCIÓN CON POLVO POR RAYOS X QUE TIENE PICOS EN LOS ÁNGULOS 2Θ DE 7,5, 9,3, 14,5, 18,8, 21,3, Y 24,8° ± 0,2°; II) LA FORMA 7, Y TIENE UN PATRÓN DE DIFRACCIÓN CON POLVO POR RAYOS X QUE TIENE PICOS EN ÁNGULOS 2Θ DE 14,1, 19,1, 21,8, 23,5, Y 25,7° ± 0,2°; III) LA FORMA 8, Y TIENE UN PATRÓN DE DIFRACCIÓN CON POLVO POR RAYOS X QUE TIENE PICOS EN LOS ÁNGULOS 2Θ DE 9,0, 9,2, 21,9, 22,1, 24,2, Y 24,6° ± 0,2°; Y IV) LA FORMA 9, TIENE UN PATRÓN DE DIFRACCIÓN CON POLVO POR RAYOS X QUE TIENE PICOS EN LOS ÁNGULOS 2Θ DE 6,5, 19,6, 20,1, Y 21,6° ±0,2°. SE DESCRIBE ADEMÁS EL USO DE LAS FORMAS CRISTALINAS EN LA MANUFACTURA DE MEDICAMENTOS ÚTILES EN EL TRATAMIENTO DE NEOPLASIA HEMATOLÓGICA AVANZADA Y; COMPOSICIONES FARMACÉUTICAS QUE CONTIENE DICHAS FORMAS CRISTALINAS AISLADAS.</p>
CL2017002240A 2013-08-02 2017-09-04 Formas cristalinas del compuesto 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol metanosulfonato; composición farmacéutica; usos en el tratamiento de neoplasias hematológicas avanzadas (divisional solicitud 263-2016). CL2017002240A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361861884P 2013-08-02 2013-08-02
PCT/CN2013/081170 WO2015018060A1 (en) 2013-08-09 2013-08-09 Crystalline forms of therapeutically active compounds and use thereof
US201461939098P 2014-02-12 2014-02-12
US201461975448P 2014-04-04 2014-04-04
US201462011948P 2014-06-13 2014-06-13
CL2016000263A CL2016000263A1 (es) 2013-08-02 2016-02-02 Compuestos terapéuticamente activos y sus métodos de uso.

Publications (1)

Publication Number Publication Date
CL2017002240A1 true CL2017002240A1 (es) 2018-04-20

Family

ID=52432592

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016000263A CL2016000263A1 (es) 2013-08-02 2016-02-02 Compuestos terapéuticamente activos y sus métodos de uso.
CL2017002240A CL2017002240A1 (es) 2013-08-02 2017-09-04 Formas cristalinas del compuesto 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol metanosulfonato; composición farmacéutica; usos en el tratamiento de neoplasias hematológicas avanzadas (divisional solicitud 263-2016).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016000263A CL2016000263A1 (es) 2013-08-02 2016-02-02 Compuestos terapéuticamente activos y sus métodos de uso.

Country Status (21)

Country Link
US (6) US9738625B2 (es)
EP (3) EP3566706B1 (es)
JP (3) JP6742905B2 (es)
CN (3) CN110372670B (es)
AU (2) AU2014295938B2 (es)
BR (1) BR112016002287A2 (es)
CA (1) CA2919382A1 (es)
CL (2) CL2016000263A1 (es)
EA (1) EA030428B1 (es)
ES (1) ES2886211T3 (es)
IL (2) IL243833A0 (es)
MX (2) MX389250B (es)
MY (1) MY177994A (es)
NI (1) NI201600022A (es)
PE (1) PE20160840A1 (es)
PH (1) PH12016500164B1 (es)
SA (1) SA516370523B1 (es)
SG (2) SG11201600479WA (es)
TW (2) TWI666208B (es)
UA (1) UA121021C2 (es)
WO (1) WO2015017821A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2014295938B2 (en) * 2013-08-02 2018-07-19 Les Laboratoires Servier Therapeutically active compounds and their methods of use
JP2017529382A (ja) * 2014-09-29 2017-10-05 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性を有する化合物及びその使用方法
JP7220986B6 (ja) 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法
CN107922354B (zh) * 2015-05-07 2021-05-25 苏州韬略生物科技有限公司 作为idh2抑制剂的杂环化合物
DK3330258T3 (da) * 2015-07-30 2021-08-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10695352B2 (en) * 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
KR20180063125A (ko) 2015-10-15 2018-06-11 아지오스 파마슈티컬스 아이엔씨. 악성종양을 치료하기 위한 복합 요법
CA3002531C (en) * 2015-10-21 2020-08-18 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof
ES2905915T3 (es) 2015-12-04 2022-04-12 Servier Lab Procedimientos de tratamiento de neoplasias malignas
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
MA43640A (fr) * 2016-02-26 2018-11-28 Agios Pharmaceuticals Inc Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
EP3493809B1 (en) 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
MX392941B (es) 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
ES2924500T3 (es) * 2017-01-22 2022-10-07 Chia Tai Tianqing Pharmaceutical Group Co Ltd Sal de derivado de 1,3,5-triazina, cristal, método de preparación, composición farmacéutica y uso de la misma
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
KR20200020899A (ko) 2017-06-30 2020-02-26 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
JP2023503842A (ja) 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
DE59106971D1 (de) 1990-07-12 1996-01-11 Ciba Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien.
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
AU5379900A (en) 1999-06-07 2000-12-28 Shire Biochem Inc. Thiophene integrin inhibitors
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
EP2256108B1 (en) 2002-07-18 2016-03-23 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
JP5450381B2 (ja) * 2007-04-30 2014-03-26 プロメティック・バイオサイエンスィズ・インコーポレーテッド 化合物、そのような化合物を含有する組成物、及びそのような化合物を用いるがん及び自己免疫疾患の治療法
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
WO2010144338A1 (en) 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
CA2767008C (en) * 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
PE20142098A1 (es) * 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
KR20140131955A (ko) 2012-03-09 2014-11-14 카나 바이오사이언스 인코포레이션 신규 트리아진 유도체
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2014287122B9 (en) 2013-07-11 2018-11-01 Les Laboratoires Servier N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
AU2014295938B2 (en) * 2013-08-02 2018-07-19 Les Laboratoires Servier Therapeutically active compounds and their methods of use
JP2017529382A (ja) 2014-09-29 2017-10-05 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性を有する化合物及びその使用方法
JP7220986B6 (ja) 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法

Also Published As

Publication number Publication date
CN110386922A (zh) 2019-10-29
NZ716226A (en) 2021-08-27
NI201600022A (es) 2016-03-16
US20240132474A1 (en) 2024-04-25
CN105916507A (zh) 2016-08-31
TW201524971A (zh) 2015-07-01
TWI666208B (zh) 2019-07-21
US20170305885A1 (en) 2017-10-26
IL270347B (en) 2021-08-31
AU2014295938B2 (en) 2018-07-19
PH12016500164A1 (en) 2016-04-25
US20160194305A1 (en) 2016-07-07
MX394658B (es) 2025-03-24
US20210155603A1 (en) 2021-05-27
CA2919382A1 (en) 2015-02-05
EA030428B1 (ru) 2018-08-31
JP2021176893A (ja) 2021-11-11
MY177994A (en) 2020-09-28
WO2015017821A2 (en) 2015-02-05
PE20160840A1 (es) 2016-09-22
CN110372670A (zh) 2019-10-25
EP3566706A1 (en) 2019-11-13
EP3932408A1 (en) 2022-01-05
ES2886211T3 (es) 2021-12-16
JP2016527279A (ja) 2016-09-08
MX2016001361A (es) 2016-06-14
MX389250B (es) 2025-03-20
AU2018247242A1 (en) 2018-11-01
AU2018247242B2 (en) 2020-03-12
US9738625B2 (en) 2017-08-22
BR112016002287A2 (pt) 2017-08-01
SG10201709187TA (en) 2017-12-28
UA121021C2 (uk) 2020-03-25
TWI701242B (zh) 2020-08-11
CL2016000263A1 (es) 2016-08-19
SA516370523B1 (ar) 2019-01-10
IL243833A0 (en) 2016-04-21
CN110372670B (zh) 2023-04-07
EP3566706B1 (en) 2021-07-14
US20260085059A1 (en) 2026-03-26
EA201690322A1 (ru) 2016-07-29
EP3027193A2 (en) 2016-06-08
AU2014295938A1 (en) 2016-02-18
PH12016500164B1 (en) 2023-11-08
JP2019142930A (ja) 2019-08-29
TW201932455A (zh) 2019-08-16
US10730854B2 (en) 2020-08-04
SG11201600479WA (en) 2016-02-26
JP6742905B2 (ja) 2020-08-19
EP3027193A4 (en) 2017-04-26
US10093654B2 (en) 2018-10-09
MX2020011397A (es) 2022-08-05
WO2015017821A3 (en) 2015-04-09
US20180370951A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
CL2017002240A1 (es) Formas cristalinas del compuesto 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol metanosulfonato; composición farmacéutica; usos en el tratamiento de neoplasias hematológicas avanzadas (divisional solicitud 263-2016).
PE20171105A1 (es) Formas solidas de un inhibidor ask1
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2017001249A1 (es) Forma cristalina de sulfato de hidrógeno (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidinaa-1-il)-pirazolo[1,5-a] pirimidinaa-3-il)-3-hidroxipirrolidinaa-1-carboxamida.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
CY1120619T1 (el) Χημικες οντοτητες
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CR20160016A (es) Pirazolpiridinas sustituidas
TN2015000313A1 (en) Chemical compounds
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
EA201591649A1 (ru) Составы с органическими соединениями
MX2015012386A (es) Inhibidores de la cinasa cdk9.
PE20191134A1 (es) Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f
MX382058B (es) Hidroxietil sulfonato de inhibidor de proteína cinasa dependiente de ciclina, su forma cristalina y su método de preparación.
BR112015022207A8 (pt) forma cristalina do composto i, formas cristalinas de sais do composto i e uso do composto i
NI201800065A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.
PE20181895A1 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer